CD5 CAR-engineered IL-15-transduced cord blood-derived NK cells
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for CD5 CAR-engineered IL-15-transduced cord blood-derived NK cells, covering 2026-02-02 to 2026-03-04. Get the full timeline:
Most recent: Clinical Trial Update: Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies [Phase 2]